-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The development of immune checkpoint inhibitors and BRAF and MEK targeted therapies has led to a radical change in the survival outcomes of patients with advanced melanoma
.
In particular, the programmed cell death 1 inhibitors nivolumab and pembrolizumab and the cytotoxic T lymphocyte-associated protein 4 blocking antibody ipilimumab have reshaped the immunological approach to the treatment of this disease
immunity
In the Phase III CheckMate 067 trial, compared with ipilimumab, the long-lasting clinical benefit of nivolumab combined with ipilimumab and nivolumab alone has been verified
.
This article reports the efficacy and safety prognosis of the trial at a follow-up of 6.
Patients with untreated and unresectable stage III-IV melanoma were randomly divided into three groups 1:1:1, and the combination group received nivolumab (1 mg/kg) combined with ipilimumab (3 mg/kg) , Once every 3 weeks, a total of 4 times, then changed to nivolumab (3 mg/kg), once every 2 weeks (n=314); nivolumab group received nivolumab (3 mg/kg), 2 Once a week (n=316); the ipilimumab group received ipilimumab (3 mg/kg), once every 3 weeks (4 times, n=315)
.
The primary endpoints are progression-free survival and overall survival (OS)
The median PFS and OS of the three groups
The median PFS and OS of the three groupsAfter the shortest follow-up of 6.
5 years, the median OS of the combination group, nivolumab group, and ipilimumab group were 72.
1 months, 36.
9 months, and 19.
9 months, respectively
.
The median melanoma-specific survival (MSS) of the combination group, nivolumab group, and ipilimumab group were unreached, 58.
The median OS of the combination group, nivolumab group and ipilimumab group were 72.
Three groups of MSS
Three groups of MSSIn summary, the results of the CheckMate 067 trial followed up for 6.
5 years are the longest reported median OS so far and the first phase III melanoma trial that reported MSS.
The results show that compared with ipilimumab, nivolumab Combination of ipilimumab or ipilimumab alone can significantly improve the clinical prognosis of advanced melanoma; and the efficacy of nivolumab combined with ipilimumab is better than that of nivolumab monotherapy
.
Wumab monotherapy
.
Compared with ipilimumab, nivolumab combined with ipilimumab or ipilimumab alone can significantly improve the clinical prognosis of advanced melanoma; and the efficacy of nivolumab combined with ipilimumab is better than that of navolumab.
Original source:
Wolchok et al.
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma in this message
